Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2023-12-01 00:00:00 ET · period of report 2023-11-30 · accession 0001415889-23-015701 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-01 | 2023-11-30 | OLMA | Harmon Cyrus | Dir | S - Sale | $12.57 | -25.0K | 926.3K | -3% | -$314.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-30 | S | D | 25,000 | $12.57 | 926,283 | D | — | — | (F2) The weighted average sale price for the transaction reported was $12.57, and the range of prices was between $12.30 and $13.02. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |